Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 7.3% – Should You Buy?

Shares of Ascendis Pharma A/S (NASDAQ:ASND) shot up 7.3% during mid-day trading on Monday . The company traded as high as $266.17 and last traded at $266.06. Approximately 172,528 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 669,456 shares. The stock had previously closed at $247.91.

Key Stories Impacting Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: BioMarin settlement removes litigation overhang: Ascendis and BioMarin entered a binding term sheet for a global settlement and license agreement covering YUVIWEL® and navepegritide-related products. The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty around the product. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL Shares increased following news of the license deal. Ascendis Pharma Shares Rise 6% Over License Deal With BioMarin Pharmaceutical
• Positive Sentiment: Wedbush remains bullish: Wedbush reaffirmed its “Outperform” rating and set a $327 price target, implying substantial upside from the referenced share price. The rating signals continued confidence in Ascendis’ growth prospects and product pipeline. Wedbush Reaffirms Ascendis Pharma Outperform Rating
• Neutral Sentiment: Analyst consensus remains favorable: Ascendis Pharma received an average analyst rating of “Buy,” indicating that Wall Street sentiment remains broadly positive despite recent estimate revisions. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Negative Sentiment: HC Wainwright cuts forward EPS forecasts: The firm reduced its estimates for the third and fourth quarters of 2026, all four quarters of 2027, and FY2027 EPS to $11.25 from $11.88. Although HC Wainwright maintained its “Buy” rating and $345 price target, the lower forecasts suggest a more cautious outlook for near-term earnings growth.
• Negative Sentiment: Bank of America trims its target: Bank of America lowered its price objective to $304 from $306 while retaining a “Buy” rating, representing a modest reduction in expected upside.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Bank of America cut their price objective on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday. Morgan Stanley reduced their target price on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating for the company in a research report on Tuesday. Wells Fargo & Company reduced their price objective on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $312.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and a consensus price target of $310.05.

Ascendis Pharma A/S Price Performance

The business has a 50-day moving average price of $256.87 and a two-hundred day moving average price of $239.75. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $16.23 billion, a price-to-earnings ratio of 20.19 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, research analysts anticipate that Ascendis Pharma A/S will post 3.9 EPS for the current year.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 2,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the purchase, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 40.00% of the stock is owned by corporate insiders.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at $166,367,000. Wellington Management Group LLP lifted its stake in shares of Ascendis Pharma A/S by 95.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after purchasing an additional 880,836 shares during the period. Vestal Point Capital LP raised its position in shares of Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after buying an additional 400,000 shares during the last quarter. Principal Financial Group Inc. raised its position in Ascendis Pharma A/S by 29.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after purchasing an additional 232,730 shares during the period. Finally, California State Teachers Retirement System bought a new position in shares of Ascendis Pharma A/S during the second quarter valued at approximately $50,011,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.